ESMO: Breakthroughs in Melanoma Treatment Regimens

Source: Medscape, April 2024

Hello. I’m Dr Jeffrey Weber. I’m a medical oncologist at the Laura and Isaac Perlmutter Cancer Center in New York City at NYU Langone Health. I’d like to report to you today on three abstracts from the recent ESMO meeting. I think they are of some interest to both practicing doctors and those interested in the academic melanoma world.

First is an update on the SECOMBIT trial, a clinical trial in which patients with metastatic melanoma were randomly allocated to get either targeted therapy with encorafenib and imatinib first and then on progression get ipilimumab/nivolumab (ipi/nivo)(arm A); or to get ipi/nivo first and then get targeted therapy second (arm B).

Arm C was the sandwich arm: Patients got 8 weeks of encorafenib and imatinib and then had a forced switch to immunotherapy; if they progressed, they went on potentially to get targeted therapy. The preliminary results of that have already been presented.
READ THE ORIGINAL FULL ARTICLE